|
NCI PREVENT Cancer Program – Upcoming Research Support Opportunity in Cancer Prevention & Interception: Applications Due November 4, 2024
Are you someone actively looking for resources to bolster your research in cancer preventive agent development? The NCI PREVENT Cancer Preclinical Drug Development Program (PREVENT) is a peer-reviewed program that supports the preclinical development of innovative interventions and predictive biomarkers for cancer prevention and interception towards clinical applications in high-risk populations. All interested researchers from academia, industry, non-profits, and government with innovative ideas in precision cancer prevention are encouraged to apply.
Deadline: Monday, November 4, 2024.
PREVENT’s current research priority areas are:
- Immunoprevention
- Chemoprevention
- Clinically translatable, response-predictive biomarkers
For more information on Program support, types of supported projects, and the application visit the PREVENT web page.
|
|
|
Microbial Host Defense and Effect on Cancer Initiation and Progression
Wednesday, September 11
1:00–2:00 p.m. ET
Advance registration required
Florencia McAllister, M.D., associate professor at the University of Texas MD Anderson Cancer Center, will give a talk tomorrow on microbial host defense and effect on cancer as part of the NCI DCP Immunology Interest Group Seminar Series.
Learn more about the seminar.
|
Environmental Exposure: HPV-related Head and Neck Cancer Webinar
Thursday, September 12
12:00–1:30 p.m. ET
Advance registration required
Nisha J D'Silva (left), B.D.S, M.S.D., Ph.D., professor of dentistry at the University of Michigan, will give a presentation on HPV-positive oropharyngeal cancer. Karen Anderson (right), Ph.D., professor at Arizona State University, will then present on strategies for early detection of HPV head and neck squamous cell carcinoma. This webinar is sponsored by the NCI DCP Environmental Sciences and Cancer Prevention Interest Group.
Learn more about the webinar.
|
NCI at the 2024 World Cancer Congress
 Tuesday, September 17-Thursday, September 19
Geneva, Switzerland
Advance registration required
On September 17, Lori Minasian, M.D., deputy director of DCP, will present plans for trials and regulation on multi-cancer early detection tests in the United States. On September 18, Phil Castle, Ph.D., director of DCP, will present the successes and failures of HPV prevention programs in reducing cervical cancer burden.
Learn more about all the NCI presentations at the World Cancer Congress.
Lung Cancer Screening in G7 Cancer Countries: Challenges and Lessons Learned
|
|
|
|
